Clinical significant of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse

Leukemia

Volumn 18, Issue 3, 2004, Pages 499-504

  Coustan Smith, E ^a   Gajjar, A ^a,c   Hijiya, N ^a,c   Razzouk, B I ^a,c   Ribeiro, R C ^a,c   Rivera, G K ^a,c   Rubnitz, J E ^a,c   Sandlund, J T ^a,c   Andreansky, M ^a   Hancock, M L ^b   Pui, C H ^a,c   Campana, Dario ^a,c  

^a Children's Research Hospital   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Acute lymphoblastic leukemia; Flow cytometry; Minimal residual disease; Relapse

Indexed keywords

ASPARAGINASE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; HYDROCORTISONE; METHOTREXATE; TOPOTECAN; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BIOASSAY; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RECURRENCE; CELL STRUCTURE; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INFANT; LEUKEMIA CELL; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; SAMPLING; SECOND CANCER; STATISTICAL ANALYSIS; ACUTE LYMPHOCYTIC LEUKEMIA; BONE MARROW; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; REMISSION; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION;

EID: 1542503795     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403283     Document Type: Article

References (46)

1. Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukemia - current status and future perspectives. Lancet Oncol 2001; 2: 597-607.
2. Chessells JM. Relapsed lymphoblastic leukaemia in children: A continuing challenge. Br J Haematol 1998; 102: 423-438.
3. Rivera GK, Buchanan G, Boyett JM, Camitta B, Ochs J, Kalwinsky D et al. Intensive retreatment of childhood acute lymphoblastic leukemia in first bone marrow relapse. A Pediatric Oncology Group Study. N Engl J Med 1986; 315: 273-278.
4. Buchanan GR, Rivera GK, Boyett JM, Chauvenet AR, Crist WM, Vietti TJ. Reinduction therapy in 297 children with acute lymphoblastic leukemia in first bone marrow relapse: A Pediatric Oncology Group Study. Blood 1988; 72: 1286-1292.
5. Henze G, Fengler R, Hartmann R, Kornhuber B, Janka-Schaub G, Niethammer D et al. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. Blood 1991; 78: 1166-1172.
6. Sadowitz PD, Smith SD, Shuster J, Wharam MD, Buchanan GR, Rivera GK. Treatment of late bone marrow relapse in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood 1993; 81: 602-609.
7. von der Weid N, Wagner B, Angst R, Arnet B, Baumgartner C, Beck D et al. Treatment of relapsing acute lymphoblastic leukemia in childhood. III. Experiences with 54 first bone marrow, nine isolated testicular, and eight isolated central nervous system relapses observed 1985-1989. Med Pediatr Oncol 1994; 22: 361-369.
8. Miniero R, Saracco P, Pastore G, Zurlo MG, Terracini B, Rosso P et al. Relapse after first cessation of therapy in childhood acute lymphoblastic leukemia: A 10-year follow-up study. Italian Association of Pediatric Hematology-Oncology (AIEOP). Med Pediatr Oncol 1995; 24: 71-76.
9. Feig SA, Harris RE, Sather HN. Bone marrow transplantation versus chemotherapy for maintenance of second remission of childhood acute lymphoblastic leukemia: A study of the Children's Cancer Group (CCG-1884). Med Pediatr Oncol 1997; 29: 534-540.
10. Rivera GK, Hudson MM, Liu Q, Benaim E, Ribeiro RC, Crist WM et al. Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia. Blood 1996; 88: 831-837.
11. Giona F, Testi AM, Rondelli R, Amadori S, Arcese W, Meloni G et al. ALL R-87 protocol in the treatment of children with acute lymphoblastic leukaemia in early bone marrow relapse. Br J Haematol 1997; 99: 671-677.
12. Gaynon PS, Qu RP, Chappell RJ, Willoughby ML, Tubergen DG, Steinherz PG et al. Survival after relapse in childhood acute lymphoblastic leukemia: Impact of site and time to first relapse - the Children's Cancer Group Experience. Cancer 1998; 82: 1387-1395.
13. Yumura-Yagi K, Hara J, Horibe K, Tawa A, Komada Y, Oda M et al. Outcome after relapse in childhood acute lymphoblastic leukemia. Int J Hematol 2002; 76: 61-68.
14. Buchanan GR, Rivera GK, Pollock BH, Boyett JM, Chauvenet AR, Wagner H et al. Alternating drug pairs with or without periodic reinduction in children with acute lymphoblastic leukemia in second bone marrow remission: A Pediatric Oncology Group Study. Cancer 2000; 88: 1166-1174.
15. Schroeder H, Garwicz S, Kristinsson J, Siimes MA, Wesenberg F, Gustafsson G. Outcome after first relapse in children with acute lymphoblastic leukemia: A population-based study of 315 patients from the Nordic Society of Pediatric Hematology and Oncology (NOPHO). Med Pediatr Oncol 1995; 25: 372-378.
16. Morris EC, Harrison G, Bailey CC, Hann IM, Hill FG, Gibson BE et al. Prognostic factors and outcome for children after second central nervous system relapse of acute lymphoblastic leukaemia. Br J Haematol 2003; 120: 787-789.
17. Buhrer C, Hartmann R, Fengler R, Dopfer R, Gadner H, Gerein V et al. Superior prognosis in combined compared to isolated bone marrow relapses in salvage therapy of childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1993; 21: 470-476.
18. Wheeler K, Richards S, Bailey C, Chessells J. Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukaemia: The MRC UKALL X experience. Medical Research Council Working Party on Childhood Leukaemia. Br J Haematol 1998; 101: 94-103.
19. Beyermann B, Agthe AG, Adams HP, Seeger K, Linderkamp C, Goetze G et al. Clinical features and outcome of children with first marrow relapse of acute lymphoblastic leukemia expressing BCR-ABL fusion transcripts. BFM Relapse Study Group. Blood 1996; 87: 1532-1538.
20. Brisco MJ, Condon J, Hughes E, Neoh SH, Sykes PJ, Seshadri R et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 1994; 343: 196-200.
21. Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group. N Engl J Med 1998; 339: 591-598.
22. Coustan-Smith E, Behm FG, Sanchez J, Boyett JM, Hancock ML, Raimondi SC et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998; 351: 550-554.
23. van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731-1738.
24. Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000; 96: 2691-2696.
25. Nyvold C, Madsen HO, Ryder LP, Seyfarth J, Svejgaard A, Clausen N et al. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood 2002; 99: 1253-1258.
26. Dworzak MN, Froschl G, Printz D, Mann G, Potschger U, Muhlegger N et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002; 99: 1952-1958.
27. Pui CH, Campana D. New definition of remission in childhood acute lymphoblastic leukemia. Leukemia 2000; 14: 783-785.
28. Campana D. Determination of minimal residual disease in leukemia patients. Br J Haematol 2003; 121: 823-838.
29. Steenbergen EJ, Verhagen OJ, van Leeuwen EF, van den Berg H, Behrendt H, Slater RM et al. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia. Leukemia 1995; 9: 1726-1734.
30. Eckert C, Biondi A, Seeger K, Cazzaniga G, Hartmann R, Beyermann B et al. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet 2001; 358: 1239-1241.
31. Coustan-Smith E, Sancho J, Behm FG, Hancock ML, Razzouk BI, Ribeiro RC et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 2002; 100: 52-58.
32. Campana D, Coustan-Smith E. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2002; 15: 1-19.
33. Wall AM, Gajjar A, Link A, Mahmoud H, Pui CH, Relling MV. Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia. Leukemia 2000; 14: 221-225.
34. Edick MJ, Gajjar A, Mahmoud HH, van de Poll ME, Harrison PL, Panetta JC et al. Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. J Clin Oncol 2003; 21: 1340-1346.
35. Coustan-Smith E, Sancho J, Hancock ML, Razzouk BI, Ribeiro RC, Rivera GK et al. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood 2002; 100: 2402.
36. Coustan-Smith E, Ribeiro RC, Rubnitz JE, Razzouk BI, Pui CH, Pounds S et al. Clinical significance of residual disease during treatment in childhood acute myeloid leukemia. Br J Haematol 2003; 123: 243.
37. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons, 1980.
38. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
39. Fine JP, Gray J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
40. Gadner H, Haas OA, Masera G, Pui CH, Schrappe M. 'Ponte di Legno' Working Group - report on the Fifth International Childhood Acute Lymphoblastic Leukemia Workshop: Vienna, Austria, 29 April-1 May 2002. Leukemia 2003; 17: 798-803.
41. Borgmann A, Von Stackelberg A, Hartmann R, Ebell W, Klingebiel T, Peters C et al. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: A matched-pair analysis. Blood 2003; 101: 3835-3839.
42. Radich J, Gehly G, Lee A, Avery R, Bryant E, Edmands S et al. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood 1997; 89: 2602-2609.
43. Knechtli CJC, Goulden NJ, Hancock JP, Grandage VLG, Harris EL, Garland RJ et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 1998; 92: 4072-4079.
44. van der Velden V, Joosten SA, Willemse MJ, Van Wering ER, Lankester AW, van Dongen JJ et al. Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia. Leukemia 2001; 15: 1485-1487.
45. Bader P, Hancock J, Kreyenberg H, Goulden NJ, Niethammer D, Oakhill A et al. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia 2002; 16: 1668-1672.
46. Goulden N, Bader P, van der Velden V, Moppett J, Schilham M, Masden HO et al. Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia. Br J Haematol 2003; 122: 24-29.